Epistem’s Biomarker Focus in the US
News Oct 30, 2009
Epistem Plc will open a US office based in Boston, MA to increase its presence in the all important North American Market. The US office (Epistem Inc) will maximize the awareness of Epistem Plc’s technology offering as well as support the commercialization of the recently launched proprietary GenetRx™ biomarker platform in oncology.
GenetRx™ is the company’s cDNA gene expression profiling technology which has the ability to analyze individual plucked hairs, blood and other tissue samples which are traditionally difficult or too small to analyze by other methods. This proprietary technology is used by clinicians and research scientists to study target engagement and pharmacodynamic effects of a drug and to establish dose scheduling, drug effect, and patient response.
Epistem Plc has been successful in applying its know-how and expertise in adult epithelial stem cells to the areas of oncology and gastrointestinal disease, as well as other applications in dermatology.
Epistem’s biomarker collaborations in North America will focus on preclinical and clinical oncology drug development providing a means of translating drug effect in specific oncology pathways such as Hedgehog, WNT, Notch, Beta Catenin, PI3 kinase and androgen signalling as well as providing an ideal platform for evaluating therapies aimed at specific RNA targets. The Biomarker Laboratory services will be delivered within a regulatory framework to comply with Good Clinical Laboratory Practice (GcLP).
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE